<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This article focuses on the potential role of <z:chebi fb="0" ids="25354">mineralocorticoid</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> (MRAs) in patients with stage B <z:hpo ids='HP_0001635'>heart failure</z:hpo> (HF) due to <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, and/or visceral <z:hpo ids='HP_0001513'>obesity</z:hpo> with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>It briefly discusses the role of MRAs in patients with left <z:hpo ids='HP_0002119'>ventricular dilatation</z:hpo> due to nonischemic or ischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and in those with a prior <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> but without left <z:hpo ids='HP_0002119'>ventricular dilatation</z:hpo> or evidence of HF </plain></SENT>
</text></document>